MA-EXAGRID
24.1.2022 14:02:12 CET | Business Wire | Press release
ExaGrid ® , the industry’s only Tiered Backup Storage solution, today announced that a newly published ESG technical review, ExaGrid with Commvault: Maximum Deduplication Savings with Easy Management authored by Kerry Dolan, Sr. IT Validation Analyst and Craig Ledo, IT Validation Analyst, documents ESG’s validation of ExaGrid testing that demonstrated both the capacity savings and ease of use available from a combined ExaGrid and Commvault backup solution. The data deduplication from Commvault can remain turned on and ExaGrid furthers the Commvault deduplication by a factor of 3:1.
From the ESG report:
“It is well known that both ExaGrid and Commvault offer backup solutions that are easy to use and can help you to store data more efficiently with deduplication. What may be less well known is that a combined ExaGrid and Commvault solution can achieve even greater deduplication: up to 20:1 in many cases. A 20x reduction in backup storage costs can be a significant boost to any budget.
ESG validated that:
- The combined ExaGrid/Commvault solution reduced a 123TB backup data set that included 15 days of file data, VMware VMs, and SQL database backups down to 8.66TB, a 14:1 reduction, in a realistic yet intentionally conservative test environment.
- Deploying and managing the combined solution was simple, intuitive, and fast.”
ExaGrid Tiered Backup Storage requires close integration between the backup software and the backup storage. Together, Commvault and ExaGrid provide a cost-effective backup solution that scales to meet the needs of demanding enterprise environments. ExaGrid improves the storage economics of Commvault environments by working with Commvault deduplication on to provide up to 20:1 reduction in storage consumption – a 3X storage savings over using Commvault deduplication alone. This combination dramatically lowers the cost of onsite and offsite backup storage.
Commvault deduplicated data can be sent to ExaGrid appliances for further deduplication. ExaGrid takes the average 5:1 Commvault deduplication ratio up to 15:1 which reduces the storage footprint by 300%. This greatly reduces the cost of the backup storage while allowing no change to the current Commvault configuration since the Commvault deduplication can remain on. In this example, ExaGrid can replicate the 15:1 deduplicated data to a second site for offsite long-term retention and disaster recovery. The additional deduplication saves WAN bandwidth in addition to saving storage at both sites.
“ExaGrid continues to innovate to optimize integration with the backup applications we support, providing our customers with unique benefits for the backup applications that they use. We have been able to further deduplicate Commvault’s deduped data for some time now to maximize storage savings, and this new report highlights how well this actually works, all without requiring current Commvault users to make changes to their configuration,” said Bill Andrews, President and CEO of ExaGrid. “We hope that current Commvault users and those who are planning to use Commvault will take a look at this report and consider the storage savings that ExaGrid can bring to their backup environment. Separately, ExaGrid can greatly improve Commvault backup and restore performance if Commvault deduplication is turned off. In this case, ExaGrid provides the same storage savings but with greatly improved backup and restore performance. ExaGrid gives Commvault customers the option to keep Commvault deduplication turned on, or for improved performance, turned off.”
About ExaGrid
ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The retention repository offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and product obsolescence. ExaGrid offers the only two-tiered backup storage approach with a non-network-facing tier, delayed deletes, and immutable objects to recover from ransomware attacks. Visit us at exagrid.com or connect with us on LinkedIn . See what our customers have to say about their own ExaGrid experiences and learn why they now spend significantly less time on backup in our customer success stories .
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220124005138/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom